ArticleNPJ breast cancer2026
Comprehensive genomic analysis of non-BRCA familial breast cancer in an Arab population.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing Germline Genetic Testing for Breast Cancer in Resource-Restricted Settings: Evidence, Barriers, and a Practical Roadmap for Implementation.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The Middle East and North African (MENA) region broadly mirrors global cancer trends, with breast cancer remaining the most common cancer among women. However, regional differences in germline BRCA1/2 mutation prevalence suggest the presence of additional genetic risk factors across MENA subgroups. We analyzed whole genome sequencing data from 180 non-BRCA familial breast cancer patients from Jordan and approximately 6000 healthy Arab controls to identify rare germline variants in cancer genes, and to evaluate the performance of existing breast cancer polygenic risk scores (PRS). Three loss-of-function variants in the high-penetrance breast cancer genes TP53 and PALB2 were exclusively observed in patients, including one TP53 variant of uncertain significance. Multiple pathogenic or likely pathogenic variants were detected in moderate-penetrance breast cancer genes, including ATM and BARD1, with ATM showing significant enrichment in gene burden analysis (OR = 14.84). Two rare loss-of-function variants in PASK and CHEK1, lacking clinical significance, were observed in multiple patients but not in controls. PRS assessment identified four PRSs with good discriminatory power (AUC > 0.690), with PGS003738 showing the highest performance (AUC = 0.702, top decile OR = 3.57). These findings highlight the need for population-specific genetic studies to improve breast cancer risk stratification in Arab populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.